NervGen Pharma Statistics
Total Valuation
NervGen Pharma has a market cap or net worth of 190.01 million. The enterprise value is 179.44 million.
| Market Cap | 190.01M |
| Enterprise Value | 179.44M |
Important Dates
The next estimated earnings date is Thursday, August 14, 2025.
| Earnings Date | Aug 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 72.83M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +17.34% |
| Shares Change (QoQ) | +0.97% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 60.97M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 196.56 |
| P/TBV Ratio | 291.02 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -10.07 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.06, with a Debt / Equity ratio of 0.06.
| Current Ratio | 1.06 |
| Quick Ratio | 1.03 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -253.35% and return on invested capital (ROIC) is -158.74%.
| Return on Equity (ROE) | -253.35% |
| Return on Assets (ROA) | -68.24% |
| Return on Invested Capital (ROIC) | -158.74% |
| Return on Capital Employed (ROCE) | -1,871.04% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +24.51% in the last 52 weeks. The beta is 0.60, so NervGen Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.60 |
| 52-Week Price Change | +24.51% |
| 50-Day Moving Average | 2.79 |
| 200-Day Moving Average | 2.15 |
| Relative Strength Index (RSI) | 43.25 |
| Average Volume (20 Days) | 148,861 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -18.09M |
| Pretax Income | -17.82M |
| Net Income | -17.82M |
| EBITDA | -18.06M |
| EBIT | -18.09M |
| Earnings Per Share (EPS) | -0.25 |
Balance Sheet
The company has 10.07 million in cash and 56,937 in debt, giving a net cash position of 10.01 million.
| Cash & Cash Equivalents | 10.07M |
| Total Debt | 56,937 |
| Net Cash | 10.01M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 966,694 |
| Book Value Per Share | 0.01 |
| Working Capital | 652,915 |
Cash Flow
| Operating Cash Flow | -12.32M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NervGen Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.34% |
| Shareholder Yield | n/a |
| Earnings Yield | -9.38% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |